Browse

At the level of the European Union there are legislative initiatives designed to create a business environment favourable to research and innovation which promotes the competitiveness of the pharmaceutical sector. When examining the compatibility with EU law of the conditions for the retail supply of medicinal products, the Court of Justice of the European Union stated that the health and life of humans rank first among the values and interests protected by the TFEU and that Member States are responsible for decid...

Among the drug classes recently introduced into therapy in the second half of the 20th century, drugs with depressant action on the central nervous system are indisputably in the lead. Given the changes occurring in the daily lifestyle, as well as the stressful daily challenges and their impact on the functionality of the CNS, research and trials aimed towards combating nervous tension have led to the emergence of a drug class currently called anxiolytics. A major success in this regard was achieved by the introdu...

In the contemporary era, the right to health is a human right and is based on the natural rights of humans. Hence the obligation of the states to develop appropriate legislation and to implement this obligation. In other words, the social responsibility in health. Currently, in Europe there is a close collaboration between the World Health Organization, the European Union and the Council of Europe with the declared aim to support the implementation of coordinated strategies for the implementation of patient rights...